Last reviewed · How we verify
Enclitide Chloride
Enclitide Chloride is a chloride channel blocker Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 2 development for Treatment of chemotherapy-induced neuropathic pain. Also known as: MK-0616.
Enclitide chloride is a chloride channel blocker.
Enclitide chloride is a chloride channel blocker. Used for Treatment of chemotherapy-induced neuropathic pain.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 2 attrition
-2.0pp
Oncology drugs have higher Phase 2-to-Phase 3 attrition than average — many fail to show OS benefit in larger studies. -
Big-pharma sponsor
+3.0pp
Merck Sharp & Dohme LLC is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Enclitide Chloride |
|---|---|
| Also known as | MK-0616 |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | chloride channel blocker |
| Target | chloride channel |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
It works by blocking chloride channels in the body, which can help to reduce inflammation and alleviate symptoms associated with certain conditions.
Approved indications
- Treatment of chemotherapy-induced neuropathic pain
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enclitide Chloride CI brief — competitive landscape report
- Enclitide Chloride updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Enclitide Chloride
What is Enclitide Chloride?
How does Enclitide Chloride work?
What is Enclitide Chloride used for?
Who makes Enclitide Chloride?
Is Enclitide Chloride also known as anything else?
What drug class is Enclitide Chloride in?
What development phase is Enclitide Chloride in?
What are the side effects of Enclitide Chloride?
What does Enclitide Chloride target?
Related
- Drug class: All chloride channel blocker drugs
- Target: All drugs targeting chloride channel
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Treatment of chemotherapy-induced neuropathic pain
- Also known as: MK-0616
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing